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Abstract
Background: Apoptolidin is a macrolide originally identified on
the basis of its ability to selectively kill E1A and E1A/E1B19K
transformed rat glial cells while not killing untransformed glial
cells. The goal of this study was to identify the molecular target of
this newly discovered natural product.
Results : Our approach to uncovering the mechanism of action
of apoptolidin utilized a combination of molecular and cell-based
pharmacological assays as well as structural comparisons between
apoptolidin and other macrocyclic polyketides with known
mechanism of action. Cell killing induced by apoptolidin was
independent of p53 status, inhibited by BCL-2, and dependent on
the action of caspase-9. PARP was completely cleaved in the
presence of 1 WM apoptolidin within 6 h in a mouse lymphoma cell
line. Together these results suggested that apoptolidin might target
a mitochondrial protein. Structural comparisons between apopto-
lidin and other macrolides revealed significant similarity between
the apoptolidin aglycone and oligomycin, a known inhibitor of
mitochondrial F0F1-ATP synthase. The relevance of this similarity
was established by demonstrating that apoptolidin is a potent
inhibitor of the F0F1-ATPase activity in intact yeast mitochondria
as well as Triton X-100-solubilized ATPase preparations. The Ki
for apoptolidin was 4^5 WM. The selectivity of apoptolidin in the
NCI-60 cell line panel was found to correlate well with that of
several known anti-fungal natural products that inhibit the
eukaryotic mitochondrial F0F1-ATP synthase.
Significance: Although the anti-fungal activities of macrolide
inhibitors of the mitochondrial F0F1-ATP synthase such as
oligomycin, ossamycin and cytovaricin are well-documented, their
unusual selectivity toward certain cell types is not widely
appreciated. The recent discovery of apoptolidin, followed by
the demonstration that it is an inhibitor of the mitochondrial
F0F1-ATP synthase, highlights the potential relevance of these
natural products as small molecules to modulate apoptotic
pathways. The mechanistic basis for selective cytotoxicity of
mitochondrial ATP synthase inhibitors is discussed. ß 2001
Elsevier Science Ltd. All rights reserved.
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1. Introduction
Drugs that can selectively sensitize cancer cells to apo-
ptosis induction are crucial. Recently, Seto and coworkers
uncovered a novel apoptosis inducer from a screen of
compounds which can selectively sensitize E1A and E1A/
E1B19K transformed cells to apoptosis with considerable
potency [1,2] from Nocardiopsis sp. named apoptolidin [2]
(Fig. 1). Our approach to uncovering the mechanism of
action of this interesting polyketide utilized selected mo-
lecular and cell-based assays combined with structural
comparison of the molecule with other polyketides of
known mechanism. Using selected apoptolidin-sensitive
cell lines, we examined the role of key apoptosis-related
proteins such as p53, BCL-2, and caspases in apoptolidin-
induced cell death. The results of these experiments sug-
gested that apoptolidin acted upon a target associated
with the mitochondria. In parallel, we also compared the
structure of apoptolidin to that of other polyketides with a
known mechanism of action. The closest structural homo-
log to apoptolidin uncovered from the literature was the
mitochondrial F0F1-ATPase inhibitor oligomycin and the
vacuolar V-ATPase inhibitor ba¢lomycin [3,4] (Fig. 1).
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Since ba¢lomycin does not show signi¢cant selectivity in
its cytotoxicity pro¢le, we tested the ability of apoptolidin
to inhibit the mitochondrial F0F1-ATPase. Our results
con¢rmed that apoptolidin is indeed an inhibitor of the
F0F1-ATPase. Further testing of apoptolidin against the
NCI-60 cell line panel revealed that apoptolidin is a mem-
ber of a family of known macrolide antibiotics.
2. Results
2.1. Evaluation of the activity of apoptolidin against
LYas lymphoma cells
We have recently described that the apoptosis sensitivity
of a mouse B cell lymphoma cell line (LYas) appears to be
due to induction of genes that target the mitochondrial
function [5,6]. Annexin V, which preferentially binds to
phosphatidyl serine exposed on the surface of apoptotic
and necrotic cells, and propidium iodide, which stains cells
with permeabilized cytosolic membranes, were used to as-
say the cytotoxicity of apoptolidin. Fig. 2 shows the treat-
ment of LYas cells with various concentrations of apopto-
lidin up to 6 h. At 3 h post-treatment with apoptolidin,
Annexin V and propidium iodide positive cells began to
appear in the culture. The minimum concentration of
apoptolidin required for inducing apoptosis at the 3 h
time-point was 200 nM, as judged by both stains. These
results demonstrated the rapidity and potency with which
cell death was induced in the LYas cell line by the natural
product. Moreover, since LYas cells lack BCL-2 [6], this
cell line could be used to study the e¡ects of BCL-2 over-
expression on the activity of the natural product (see be-
low).
2.2. Activity of apoptolidin in p53+/+ and p533/3 cell lines
The p53 gene product is an important factor in the in-
duction of apoptosis in response to chemotherapeutic
agents. Activation of p53 results in enhanced expression
of the pro-apoptotic gene, bax. Conversely, null mutations
in the p53 gene lead to increased resistance against a vari-
ety of chemotherapeutic agents (e.g. 5-£uorouracil) that
induce alterations in nucleic acid structure and metabolism
[7]. To determine whether the cytotoxic activity of apo-
ptolidin was dependent or independent of p53 status, we
used an isogenic pair of HCT116 p533/3 and p53+/+ cell
Fig. 1. Structures of apoptolidin, ba¢lomycin, oligomycin, cytovaricin,
and ossamycin.
Fig. 2. Killing of LYas mouse lymphoma cells by apoptolidin as determined by FACS staining for Annexin V and propidium iodide.
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lines, developed by Vogelstein and coworkers [7,8]. The
lack of change in the IC50 for the natural product in the
two cell lines suggested that the cytotoxicity of apoptolidin
is independent of p53 status (Fig. 3A). Control samples
performed in parallel with 5-£uorouracil con¢rmed the
p53 dependence of this drug (Fig. 3A), as shown previ-
ously [7]. Western blots also con¢rmed the lack of expres-
sion of the p53 protein in the knockout HCT116 cells as
compared to the wild-type (wt) cells (Fig. 3B). These re-
sults demonstrate that, unlike most clinically relevant cy-
totoxic agents, the activity of apoptolidin was independent
of the p53 status of a target cell. Therefore, either apopto-
lidin acted on a target downstream of p53, or its action
involved a p53-independent apoptotic pathway.
2.3. Role of BCL-2 in apoptolidin-induced cell death
Mitochondrially associated proteins such as BCL-2 are
key targets for apoptotic signals that are directed at the
mitochondria. The p53-inducible protein Bax forms depo-
larizing pores in mitochondria and induces the opening of
a permeability transition pore composed of adenine nucle-
otide transporter (ANT) and voltage-dependent anion
channel [9^15]. In turn this perturbs the normal mitochon-
drial membrane potential (v8m) and causes mitochondrial
rupture and release of apoptogenic proteins including cy-
tochrome c and AIF [16^18]. BCL-2 binds Bax and pre-
vents its channel forming activity [9,13]. Additionally,
BCL-2 inhibits mitochondrial release of pro-apoptotic
proteins such as cytochrome c and AIF [19].
The importance of the BCL-2 protein was assessed by
transfection of bcl-2 into LYas cells as described in Section
5. LYas cells and LYas cells transfected with IRES GFP
became Annexin V positive after 8 h treatment with 1 WM
apoptolidin (Fig. 4A). In contrast, the BIG cell clone
BIG1 was completely resistant to cell death induced by
apoptolidin. To further verify that this phenotype of the
BIG1 clone was not an artifact of the transfection proce-
dure, four other BCL-2 expressing clones (BIG2^BIG5)
were also shown to be resistant to apoptolidin (data not
shown). The expression of bcl-2 in the transfected cells was
determined by Western blot analysis (Fig. 4B) and by
BCL-2 speci¢c FACS staining (data not shown). These
results demonstrated that the activity of apoptolidin was
inhibited by BCL-2. Taken together with the observation
that the cytotoxicity was p53-independent, they also sug-
gested that apoptolidin acted upon a mitochondrially as-
sociated target.
2.4. Role of caspases in apoptolidin-induced cell death
To obtain further evidence in support of the involve-
ment of mitochondria in the mode of action of apoptoli-
din, we examined the e¡ect of inhibiting various caspases
on the activity of this natural product. In particular, cas-
pase-9 was of interest, since it is activated upon the for-
mation of the complex between mitochondrially released
cytochrome c, Apaf-1, dATP, and caspase-9 [20^23]. Ac-
tivated caspase-9 can activate caspase-3 [20]. Caspase-3-
mediated cleavage of the inhibitor of caspase-activated
deoxyribonuclease (ICAD) [24] leads to the activation of
the caspase-activated deoxyribonuclease as well as cleav-
age of poly(ADP-ribose) polymerase (PARP), an impor-
tant enzyme in DNA repair [25,26].
To determine whether the cytotoxicity of apoptolidin
was caspase-dependent, caspase inhibitors with de¢ned
speci¢city were used [27]. In the presence of 140 WM z-
LEHD.fmk (Enzyme Systems, Livermore, CA, USA), a
caspase-9 speci¢c peptide inhibitor, neither 1 WM etopo-
side nor 1 WM apoptolidin induced apoptosis in LYas cells
Fig. 3. Killing of HCT116 p53 wt or 3/3 cells with apoptolidin and 5-£uorouracil. A: Cell killing measured by MTT assay of cells treated for 7 days
with drugs. Apoptolidin with p53 wt (8) or p53 3/3 (F) HCT116 cells. 5-Fluorouracil with p53 wt (b) or p53 3/3 (R). B: p53 Western blot of
HCT116 p53 wt and 3/3 cells.
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after 6 h (Fig. 5A). Moreover, the pan-caspase inhibitor,
z-VAD.fmk (Enzyme Systems, Livermore, CA, USA),
which inhibits both caspase-3 and caspase-9, was also
able to completely antagonize the activity of apoptolidin
as well as etoposide on LYas cells (Fig. 5B). In both these
experiments, etoposide was used as a control, since its
activity is caspase-9-dependent [28]. To verify the activa-
tion of caspases by apoptolidin, PARP was shown to be
completely cleaved in LYas cells after a 6 h treatment with
1 WM apoptolidin (Fig. 5C).
2.5. Structural comparison between apoptolidin, oligomycin,
and ba¢lomycin
In parallel with the above biological studies, we also
initiated studies on the chemistry of apoptolidin. Recently,
we isolated a semi-synthetic derivative of apoptolidin that
lacks the disaccharide moiety attached to C-27 but still
retains some biological activity (manuscript in prepara-
tion). This prompted us to search the chemical database
for macrolides with structural similarities to the apoptoli-
din aglycone. In particular, two natural products, oligo-
Fig. 4. Inhibition of killing by BCL-2. BIG transfected LYas cells were prepared as described in Section 5. A: Induction of Annexin V positive cells by
apoptolidin with LYas/GFP (F), LYas (8), and LYas/BIG1 (b) cells. B: Western blot for BCL-2 and actin for LYas/GFP, LYas, and LYas/BIG1
cells.
Fig. 5. Inhibition of apoptosis with the caspase-9 speci¢c inhibitor z-LEHD.fmk (A), or pan-caspase speci¢c inhibitor z-VAD.fmk (B) in LYas cells.
Cells were treated for 6 h with z-LEHD.fmk and 1 WM etoposide (R), 1 WM apoptolidin (F), no drugs (8), DMSO control (b). C: Cleavage of PARP
from 116 kDa size to activated 85 kDa fragment by 6 or 48 h treatment with 1 WM apoptolidin in LYas cells. 40 Wg protein was applied in lanes a (un-
treated cells) and b (6 h apoptolidin), whereas 13 Wg protein is applied in lane c (48 h apoptolidin).
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mycin and ba¢lomycin (Fig. 1), drew our attention. The
structures of their polyketide backbones are aligned with
that of apoptolidin in Fig. 6.
Oligomycin is an inhibitor of the mitochondrial F0F1-
ATPase [4], whereas ba¢lomycin selectively inhibits vacu-
olar ATPases [3,29]. Both molecules are known to be cy-
totoxic [29^32]. However, ba¢lomycin is relatively non-se-
lective with a GI50 value of 10 nM against 80% of the cell
lines in the NCI-60 panel (Fig. 7). In contrast, the activity
of oligomycin shows signi¢cantly greater variability
among di¡erent cell lines (Fig. 7). Approximately 35% of
the cell lines are exquisitely sensitive to this natural prod-
uct (GI50 = 10 nM); its potency against the remaining cell
lines varies between 1 and 10 WM. Similar selectivity is also
observed for ossamycin and cytovaricin (Figs. 1 and 7),
two other structurally related macrolide inhibitors of the
mitochondrial F0F1-ATPase. Compared to 37 000 other
molecules tested in the NCI-60 screen, oligomycin, ossa-
mycin, cytovaricin and apoptolidin are among the top
0.1% most cytoselective agents. In light of these as well
as the above-mentioned results, we suspected that apopto-
lidin and oligomycin might share a similar mechanism of
action.
2.6. Identi¢cation of the molecular target of apoptolidin
To test the hypothesis that apoptolidin might induce
apoptosis in eukaryotic cells by inhibiting the same target
as oligomycin, mitochondria were prepared from the lac-
tate grown yeast strain DBY7286. ATP hydrolysis by the
mitochondrial F0F1-ATPase was monitored in a coupled
enzymatic system using pyruvate kinase and lactate dehy-
drogenase. In the presence of the electron transport inhib-
itor, antimycin, our yeast mitochondrial preparations were
reproducibly found to have speci¢c ATPase activity in the
range of 1 Wmol/min/mg protein, which is similar to the
value reported by other workers in the ¢eld [4]. Moreover,
the cytochrome c oxidase activity in our preparations was
0.4 Wmol/min/mg, which also compared favorably with the
literature [4]. Using these intact mitochondrial prepara-
tions, the Ki of apoptolidin was determined to be 5 WM
(Fig. 8A). Control experiments showed that the Ki of oli-
gomycin in the same assay was 1 WM. As expected, the
vacuolar ATPase inhibitor ba¢lomycin had no inhibitory
e¡ect on ATPase activity up to 50 WM, which was the
solubility limit of the compound under our assay condi-
tions (data not shown). Control experiments, performed
using Na/K ATPase (Sigma) and the same coupled en-
zymatic assay system, con¢rmed that apoptolidin had no
e¡ect on either pyruvate kinase or lactate dehydrogenase
(data not shown). Moreover, unlike ouabain, a speci¢c
inhibitor of Na/K ATPase, apoptolidin was unable to
inhibit this enzyme at concentrations as high as 90 WM.
The above results were consistent with the hypothesis
that, like oligomycin, apoptolidin was an inhibitor of the
eukaryotic F0F1-ATPase. However, since intact mitochon-
dria were used, the possibility that apoptolidin inhibited
the mitochondrial ATP^ADP translocator (ANT), which
is required to shuttle ATP and ADP into and out of mi-
tochondria, could not be overlooked. To eliminate this
possibility, we directly assayed the activity of apoptolidin
against Triton X-100-solubilized F0F1-ATPase. Extraction
of yeast mitochondria with Triton X-100 was known to
liberate active, oligomycin-sensitive F0F1-ATPase [33,34].
As shown in Fig. 8B, the Ki of apoptolidin against solu-
bilized F0F1-ATPase (4 WM) compared well to its activity
against intact mitochondria (5 WM). In a control experi-
ment, oligomycin was con¢rmed to inhibit the activity of
Triton X-100-solubilized ATPase with a Ki of 0.1 WM.
Since ANT was not required for ATPase activity in this
assay, our results con¢rmed that apoptolidin was a potent
and selective inhibitor of the mitochondrial F0F1 ATPase.
3. Discussion
The isolation of new selective cytotoxic agents is an
important goal in the treatment of cancer. Our studies
on the mechanism of action of apoptolidin revealed the
surprising discovery that F0F1-ATP synthase inhibitors
have the potential to be selective agents, as illustrated by
the ability of apoptolidin to kill rat glial transformed cells
but not untransformed rat glial cells [2] and by the data
shown in Fig. 7. The mechanism of action of apoptolidin
was determined by a combination of targeted pharmaco-
logical assays and structural considerations. In particular,
inhibition of cell killing by BCL-2 and a caspase-9 speci¢c
inhibitor suggested that cell death signal induced by apop-
tolidin involved a mitochondria-dependent pathway.
Moreover, the total independence of apoptolidin activity
on p53 hinted that apoptolidin acted downstream of p53,
at or near the mitochondria. Finally, the fortuitous iden-
Fig. 6. Alignment of the polyketide backbones of apoptolidin, ba¢lomy-
cin, and oligomycin A. Regions that are structurally related between
apoptolidin and oligomycin or ba¢lomycin are boxed.
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Fig. 7. Cytotoxic pro¢les of apoptolidin, oligomycin A, cytovaricin, ossamycin, and ba¢lomycin against the NCI-60 cell line panel. For more informa-
tion regarding this assay, see http://dtp.nci.nih.gov/. Shown in the above bar graph is the activity (log scale) of each natural product against individual
cell lines. The mean log(GI50) values for ba¢lomycin, oligomycin A, apoptolidin, cytovaricin, and ossamycin are 37.7, 36.6, 34.7, 36, and 36.1, re-
spectively.
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ti¢cation of structural similarities between the apoptolidin
aglycone and oligomycin led us to establish that apopto-
lidin was an inhibitor of the mitochondrial ATP synthase.
Apoptolidin was originally identi¢ed on the basis of its
ability to selectively kill E1A and E1A/E1B19K trans-
formed rat glial cells while not killing untransformed glial
cells or H-ras- and v-src-transformed cells. Many cancer
cells maintain a high level of anaerobic carbon metabolism
even in the presence of oxygen, a phenomenon that is
historically known as the Warburg e¡ect [38,39]. Recent
results have led us to conclude that macrolide inhibitors of
the mitochondrial F0F1-ATP synthase selectively kill aero-
bic, metabolically active tumor cells that do not exhibit the
Warburg e¡ect [40]. Furthermore we have shown that the
master regulator of hypoxic and glycolytic gene expres-
sion, hypoxia-inducible factor 1K (HIF-1K), is expressed
in Warburg type anaerobic cells but its protein expression
is inhibited when these cells are switched to aerobic me-
tabolism [40]. Interestingly, H-ras- and v-src-transforma-
tion has been shown to induce HIF-1K protein expression
leading to a Warburg phenotype [41]. This could explain
the resistance of cell lines transformed with these onco-
genes to apoptolidin. Even though there are no available
data of changes of HIF-1K protein expression with E1A
transformation, we postulate that E1A is an aerobic trans-
formation that probably does not induce HIF-1K protein
expression and renders cells sensitive to apoptolidin.
It should be noted that, although the observed Ki for
apoptolidin is 5-fold higher than that for oligomycin, this
may be an underestimate of the potency of apoptolidin. In
the course of our chemical studies on apoptolidin, we have
observed a strong pH dependence in its stability (manu-
script in preparation). Although the natural product is
stable under acidic conditions, it rapidly degrades under
alkaline conditions. Given that mitochondrial ATPase ac-
tivity assays are typically performed at pH 8, the true Ki
for apoptolidin may be lower than that reported in this
study. Perhaps this could also account for the observation
that the IC50 values for apoptolidin against LYas cells are
substantially lower than the measured Ki against mito-
chondrial ATPase. Alternatively, this di¡erence might be
explained by a preference for mammalian ATPase over
yeast ATPase, or by the possibility that apoptosis via
this pathway is a dominant phenotype.
A recent report described the results of studies aimed at
understanding the mechanistic basis for oligomycin-in-
duced apoptosis [31]. DNA fragmentation in HL-60 cells
induced by oligomycin was inhibited by serine protease
inhibitors but not by caspase inhibitors including z-
VAD.fmk. Furthermore, DNA fragmentation was not in-
hibited by ICAD in a cell free system. Our results show
that apoptosis induced by apoptolidin in LYas cells is
inhibited by z-VAD.fmk. Consistently, apoptolidin also
induced cleavage of PARP which is known to be cleaved
by activated caspase-3 [26]. The disparity in results could
arise either due to slight di¡erences in the interactions
between these two natural products and their mitochon-
drial target, or as a result of the di¡erent assays employed
to test for the induction of apoptosis.
With the discovery of the mechanism of action of apo-
ptolidin, some intriguing questions remain to be answered.
Paradoxically, ATP synthase inhibitors such as apoptoli-
din, oligomycin, cytovaricin, and ossamycin induce apo-
ptosis, yet dATP is required for activation of caspases. A
better understanding of the precise relationships between
macrolide-mediated inhibition of the F0F1-ATPase and
the well-known mitochondrial apoptosis pathway could
provide new insights into the onset and progression of
cancer.
4. Signi¢cance
Drugs that can selectively sensitize cancer cells to apo-
ptosis induction are likely to play a vital role in cancer
therapy. Although the anti-fungal activities of macrolide
inhibitors of the mitochondrial F0F1-ATP synthase such
as oligomycin, ossamycin and cytovaricin are well-docu-
mented, their unusual selectivity toward certain cell types
is not widely appreciated. The demonstration that apopto-
lidin is an inhibitor of the mitochondrial F0F1-ATP syn-
Fig. 8. Inhibition of yeast mitochondrial ATPase activity by apoptolidin
(R) and oligomycin (F): ATPase activity was measured by a coupled
pyruvate kinase (PK), lactate dehydrogenase (LDH) enzyme assay sys-
tem. NADH oxidation was monitored at 360 nm. A: Activity against
intact mitochondria. B: Activity against 0.4% Triton X-100-solubilized
mitochondria.
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thase highlights the potential relevance of these natural
products as small molecules to modulate apoptotic path-
ways. A better understanding of the mechanistic basis for
this selective cytotoxicity might lead to increased interest
in their potential utility as chemotherapeutic agents.
5. Materials and methods
5.1. Cells
LYas and LYar cells were grown in RPMI 1640 media and are
sublines obtained from an apoptosis-sensitive B cell mouse lym-
phoma (TH-LY) [5]. HCT116 wt and p53 mutant cells were
grown in McCoy’s 5A media and were a kind gift of Dr. James
Ford [8]. All cell culture media were supplemented with 10% fetal
calf serum, 2 mM glutamine, 100 U/ml penicillin, and 50 U/ml
streptomycin and cells were grown at 37‡C, 5% CO2 in air in a
humidi¢ed incubator.
5.2. Drug additions
Apoptolidin was isolated from the producing organism as de-
scribed previously [2]. Oligomycin A, ba¢lomycin, and cyto-
chrome c were obtained from Sigma Chemical Co. (St. Louis,
MO, USA). Concentrated stock solutions of apoptolidin, oligo-
mycin, and ba¢lomycin were prepared in phosphate-bu¡ered sa-
line (PBS) with less than 1% DMSO in the ¢nal drug dilution.
5.3. Preparation of bcl-2/IRES/GFP transfected LYas cells
LYas cells containing a bcl-2/GFP expression vector (BIG) and
empty vector (GFP) were generated by adenovirus infection using
previously described methods [35]. Brie£y, helper-defective
PHOENIX-Ampho packaging lines were transfected with GFP
IRES expression vectors with or without human bcl-2 inserted
in the expression cassette. The resulting supernatants containing
viral particles were used to infect LYas cells with the respective
constructs. Cell cloning was performed by single cell FACS sort-
ing of GFP positive cells into individual wells of a 96 well plate.
Expression of BCL-2 was veri¢ed by internal staining for BCL-2
followed by FACS analysis as well as Western blot analysis.
5.4. Isolation of intact and Triton X-100-solubilized yeast
mitochondria
Yeast mitochondria were isolated from a lactate grown Saccha-
romyces cerevisiae strain DBY7286 (matA, ura3/3) according to
published procedures [36]. Brie£y, 2 l shake £asks of yeast were
grown up on semi-synthetic lactate medium at 30‡C with vigo-
rous shaking to an OD600 of 3. Cells were collected at 4000Ug
and the wet weight of the pellet was determined. Cells were con-
verted to spheroplasts by a 30 min incubation at 30‡C with 2.5
mg Zymolyase 20T (ICN Biochemicals, St. Louis, MO, USA) per
gram of packed cells in a volume of 2 ml per gram of packed cells
in bu¡er A (1.2 M sorbitol, 20 mM potassium phosphate, pH
7.4). The Zymolyase 20T was washed out twice by centrifugation
at 4000Ug and resuspension in bu¡er A. The spheroplasts were
then resuspended in bu¡er B (0.6 M sorbitol, 20 mM K MES,
pH 6.0) with 0.5 mM phenylmethylsulfonyl £uoride (PMSF) and
homogenized in a 40 ml glass Dounce homogenizer using 15
strokes with a tight-¢tting pestle. The unbroken spheroplasts
were collected by centrifugation at 1500Ug and rehomogenized
with 15 strokes in bu¡er B plus PMSF. The nuclei and unbroken
cells were separated by centrifugation at 1500Ug and the mito-
chondria were isolated from the supernatant by centrifugation at
12 000Ug for 10 min. The mitochondrial pellet was then washed
with bu¡er B and collected at 12 000Ug for 10 min. Dark brown
mitochondria were resuspended in bu¡er C (0.6 M sorbitol, 20
mM HEPES, pH 7.4). ATPase activity was measured within 6 h
of preparing mitochondria. Protein concentrations were deter-
mined by the Lowry assay (Bio-Rad, Hercules, CA, USA).
To solubilize the F0F1-ATPase that is ordinarily attached to
the inner membrane of mitochondria, 1 mg of puri¢ed yeast
mitochondria (prepared as described above) were resuspended
in 4 mM Tris/acetate, pH 7.4 [33]. This suspension was incubated
with 0.75%, 1%, or 2% Triton X-100 for 20 min at 4‡C. Solubi-
lized mitochondria were then centrifuged at 100 000Ug for 15
min at 4‡C and the supernatant was tested for ATPase activity.
5.5. Assay for yeast mitochondrial ATPase activity
Mitochondrial ATPase activity was measured by standard
methods [4]. Brie£y, 20 Wg of yeast mitochondrial protein (as
measured by the Lowry method) was added to reaction bu¡er
containing 50 mM Tris (pH 8.0), 1 mM ATP, 0.3 mM NADH,
3.3 mM MgCl2, 2 Wg/ml antimycin A, 1 mM phosphoenol pyru-
vate, 5 U/ml lactate dehydrogenase, and 2.5 U/ml pyruvate kinase
at 28‡C. Oxidation of NADH was followed at 360 nm over time.
To establish the mitochondrial origin of the ATPase activity,
published procedures were used to measure (mitochondrial) cyto-
chrome c oxidase activity [37].
5.6. FACS assay for Annexin V and propidium iodide
Cells were treated with drugs for various times and then
washed. Cells were stained with 5 Wl/test Annexin V-FITC (Bec-
ton Dickinson, San Jose, CA, USA) for 15 min and washed three
times. Next, the cells were stained with 1 Wg/ml propidium iodide
and washed two times. Cells were analyzed on the Facscan (Bec-
ton Dickinson) and the percentage of Annexin V and propidium
iodide positive cells was quanti¢ed using FlowJo software for the
Macintosh (Tree Star, Inc., San Carlos, CA, USA).
5.7. MTT assay
Drug dilutions were added to monolayer or suspension cells in
96 well plates in triplicate for varying times. MTT was then
added to the wells at a ¢nal concentration of 0.5 mg/ml. Super-
natant was removed after pelleting the reduced MTT crystals.
The crystals were fully dissolved in 40 mM HCl in isopropanol.
Plates were scanned on a microplate reader at 595 nm.
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5.8. Cytotoxicity pro¢les in the NCI-60 cell line panel
The procedures for measuring GI50 values against a panel of
selected human tumor cell lines are described on the web-site
http://dtp.nci.nih.gov/. The activities of ba¢lomycin, ossamycin,
and cytovaricin are documented on the same web-site. Oligomy-
cin A and apoptolidin were submitted for similar analysis to the
National Cancer Institute. The data are shown in Fig. 7.
5.9. Western blotting
For analysis of p53, BCL-2, and PARP expression levels, total
cellular protein was isolated by lysing cells for 1 min at 98‡C in a
bu¡er of 2% sodium dodecyl sulfate (SDS), 50 mM Tris^HCl (pH
6.8), 5% v/v glycerol, 5% 2-mercaptoethanol, 0.001% bromophe-
nol blue, pH 6.8. Protein concentration was determined by the
Lowry method (Bio-Rad, Hercules, CA, USA). Equal amounts of
protein were subjected to 15% SDS^polyacrylamide gel electro-
phoresis and electroblotted to a nitrocellulose membrane. The
membrane was blocked for 1 h in blocking bu¡er (PBS/Tween
20/10% milk) and then incubated for 4 h with 1:200 mouse anti-
human p53 antibody (DO-1, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or 1:400 hamster anti-human BCL-2 (6C8,
BD Pharmingen, San Diego, CA, USA) or 1:3000 mouse anti-
PARP (C2-10, BD Pharmingen). Membrane was then washed
2U15 min in blocking bu¡er followed by 2U15 min PBS/Tween
washes. Membrane was then stained with 1:1000 sheep anti-
mouse Ig (AP Biotech, Piscataway, NJ, USA) or 1:1000 anti-
hamster IgG (Jackson Immunoresearch, West Grove, PA) di-
rectly conjugated to horseradish peroxidase for 1 h in blocking
bu¡er and washed two times with blocking bu¡er and then two
times with PBS/Tween. Bands were visualized using chemilumi-
nescence with the ECL+ kit from AP biotech.
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